- Home
- IBRX vs ONON Comparison
IBRX vs ONON Comparison
Compare IBRX & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | ONON |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.4B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBRX | ONON |
|---|---|---|
| Price | $8.72 | $29.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | $12.57 | ★ $60.15 |
| AVG Volume (30 Days) | 9.0M | ★ 10.0M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $19.58 |
| Revenue Next Year | $131.15 | $19.98 |
| P/E Ratio | ★ N/A | $56.05 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $26.37 |
| 52 Week High | $12.43 | $51.08 |
Technical Indicators
Market Signals| Indicator | IBRX | ONON |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 53.32 |
| Support Level | $6.68 | $26.37 |
| Resistance Level | $9.54 | $31.16 |
| Average True Range (ATR) | 0.54 | 1.01 |
| MACD | 0.02 | 0.58 |
| Stochastic Oscillator | 57.88 | 72.37 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About ONON On Holding AG
Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.